New hope for hard-to-treat HER2 cancers: zanidatamab enters phase 2 trial

NCT ID NCT06695845

Recruiting now Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times

Summary

This study tests a drug called zanidatamab in about 200 adults with several types of advanced solid tumors (like breast, lung, or stomach cancer) that have high levels of HER2 protein and have worsened after at least one prior treatment. The goal is to see if zanidatamab can shrink tumors and control the disease. Participants receive the drug intravenously and are monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Oncologists
WITHDRAWN

Chicago Ridge, Illinois, 60415, United States
Alliance Cancer Specialists
WITHDRAWN

Horsham, Pennsylvania, 19044, United States
Arizona Oncology Associates, PC - NAHOA
WITHDRAWN

Prescott, Arizona, 86301, United States
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Barbara Ann Karmanos Cancer Institute
WITHDRAWN

Detroit, Michigan, 48201, United States
Blue Ridge Cancer Care
WITHDRAWN

Roanoke, Virginia, 24014, United States
Chonnam National University Hwasun Hospital
RECRUITING

Hwasun-Eup, Hwasun-Gun, 58115, South Korea
Florida Cancer Specialists - East
WITHDRAWN

West Palm Beach, Florida, 33401, United States
Florida Cancer Specialists - Lake Nona
ACTIVE_NOT_RECRUITING

Orlando, Florida, 32827, United States
Florida Cancer Specialists - North
WITHDRAWN

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists - South
WITHDRAWN

Fort Myers, Florida, 33901, United States
Hospital Regional Universitario de Malaga - Hospital General
RECRUITING

Málaga, 29010, Spain
Korea University Guro Hospital
RECRUITING

Guro-gu, Seoul, 04524, South Korea
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
National Cancer Center Suwon
RECRUITING

Suwon, Gyeonggi-do, 10408, South Korea
Rocky Mountain Cancer Center
RECRUITING

Littleton, Colorado, 80120, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Samsung Medical Center
RECRUITING

Gangnam-gu, Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seoul, 13620, South Korea
Seoul National University Hospital
RECRUITING

Jongno-gu, Seoul, 03080, South Korea
Severance Hospital
RECRUITING

Seodaemun-gu, Seoul, 03722, South Korea
Tennessee Cancer Specialists
WITHDRAWN

Knoxville, Tennessee, 37909, United States
Texas Oncology - DFW
RECRUITING

Dallas, Texas, 75246, United States
Texas Oncology - San Antonio
WITHDRAWN

San Antonio, Texas, 78217, United States
Texas Oncology - West Texas
WITHDRAWN

Amarillo, Texas, 79124, United States
The Catholic University of Korea Seoul St. Mary's Hospital
RECRUITING

Seoul, 04524, South Korea
The Catholic University of Korea St Vincent's Hospital
RECRUITING

Suwon, Gyeonggi-do, 10408, South Korea

Conditions

Explore the condition pages connected to this study.

BREAST CANCER COLORECTAL CANCER ENDOMETRIAL CANCER ENDOMETRIAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER GASTROESOPHAGEAL CANCER HER-2 PROTEIN OVEREXPRESSION HER-2 PROTEIN OVEREXPRESSION NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER SALIVARY GLAND CANCER UROTHELIAL CARCINOMA